Last reviewed · How we verify
Additional Cycle of Pembrolizumab
Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.
Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells. Used for Melanoma, Non-small cell lung cancer, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Additional Cycle of Pembrolizumab |
|---|---|
| Sponsor | Ismail Gögenur |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Pembrolizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and antigen-presenting cells. This blockade releases the 'brakes' on T-cell-mediated immunity, restoring anti-tumor immune responses. An additional cycle extends the duration of this immune checkpoint inhibition.
Approved indications
- Melanoma
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Hodgkin lymphoma
- Urothelial carcinoma
- Gastric cancer
- Cervical cancer
- Renal cell carcinoma
- Microsatellite instability-high or mismatch repair-deficient solid tumors
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Diarrhea
- Rash
- Immune-mediated pneumonitis
- Immune-mediated colitis
- Immune-mediated hepatitis
- Immune-mediated endocrinopathy
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas (PHASE3)
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (PHASE1)
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (PHASE2)
- Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery (PHASE2)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Additional Cycle of Pembrolizumab CI brief — competitive landscape report
- Additional Cycle of Pembrolizumab updates RSS · CI watch RSS
- Ismail Gögenur portfolio CI